Uracil 1-β-D-arabinofuranoside CAS 3083-77-0

Ara-U, as a nucleoside analogue, has an arabinofuranosyl group substituting for the ribose or deoxyribose in the natural nucleoside. This difference endows it with a unique antiviral mechanism. In HIV research, Ara-U can competitively inhibit the reverse transcriptase activity, blocking the process of viral RNA converting to DNA. Experimental data show that at a concentration of 10 μM, Ara-U can inhibit the reverse transcriptase activity of HIV-1 by 75%, and has a relatively small impact on the host cell DNA polymerase, demonstrating high selectivity. In influenza virus research, Ara-U has been proven to be able to incorporate into the viral RNA chain, causing chain termination or inducing lethal mutations. For example, in the H1N1 virus model, the viral replication volume in the Ara-U treatment group was reduced by more than 90% compared to the control group, and no drug-resistant strains were observed.

The antiviral application of Ara-U also extends to other RNA virus fields. In the research on hepatitis C virus (HCV), the combination of Ara-U with interferon can significantly increase the rate of sustained virological response. In the research on Ebola virus, Ara-U effectively blocks the spread of the virus within cells by inhibiting the activity of the viral polymerase. These studies provide a theoretical basis for the development of Ara-U as a broad-spectrum antiviral drug.

The application of Uracil 1-β-D-arabinofuranoside in RNA metabolism research is mainly based on its characteristic that it can be mistakenly recognized by RNA polymerase and incorporated into the RNA chain. In RNA stability studies, the incorporation of Ara-U can alter the secondary structure of RNA, affecting its interaction with ribozymes or RNA-binding proteins. For example, in tRNA research, after Ara-U replaces the uracil at a specific position, the amino acid loading efficiency of tRNA significantly decreases, revealing the crucial influence of nucleotide composition on RNA function.

In the research on RNA processing mechanisms, Ara-U has provided a new tool for exploring the assembly of the spliceosome. By marking the incorporation sites of Ara-U, researchers can track the dynamic changes of the spliceosome in real time and discover that the incorporation of Ara-U can induce the shift of splice site selection, providing a new perspective for understanding RNA splicing regulation. Moreover, Ara-U also shows unique value in RNA interference (RNAi) research. Its incorporation into siRNA or miRNA can change its binding mode with Argonaute protein, affecting the assembly and function of the RNA-induced silencing complex (RISC).

The application of Ara-U in cancer treatment mainly involves two mechanisms: directly inhibiting the proliferation of tumor cells and enhancing chemotherapy sensitivity. In lymphoma research, Uracil 1-β-D-arabinofuranoside can inhibit RNA-mediated DNA polymerase activity and block the DNA repair pathway of tumor cells. Experimental results show that treatment with 17 μM Ara-U can induce 50% inhibition of proliferation in L5178Y mouse lymphoma cells, and the effect is concentration-dependent. Further mechanism studies indicate that Ara-U induces cell cycle arrest at the G1/S phase and activates the caspase-3-dependent apoptotic pathway, exerting an anti-tumor effect.

In terms of chemotherapy sensitization, the combination of Ara-U and cytarabine (Ara-C) can significantly enhance the therapeutic effect of leukemia treatment. Ara-U inhibits the activity of deaminase, reducing the metabolic inactivation of Ara-C, thereby increasing the intracellular drug concentration by 3-5 times. Preclinical studies have shown that the Ara-U/Ara-C combination regimen can extend the median survival time of acute myeloid leukemia (AML) mouse models by 40%, with no significant increase in toxic side effects. Additionally, Ara-U can also reverse the drug resistance of tumor cells to chemotherapy drugs by down-regulating the expression of multidrug resistance protein (MDR1).

Ara-U was initially isolated from the Caribbean sponge Tectitethya crypta. Its biosynthetic pathway involves the glycosylation reaction of uracil and arabinose. Sponges build a chemical defense system by producing secondary metabolites such as Ara-U to resist pathogen invasion and predator attacks. Studies have shown that the concentration of Ara-U in sponges can reach millimolar levels, and it has significant anti-inflammatory and analgesic activities. In a mouse inflammation model, Ara-U (10mg/kg) can inhibit 50% of the release of inflammatory factors, with an effect comparable to dexamethasone (1mg/kg), and no immunosuppressive side effects were observed.

The vasodilatory property of Ara-U has also attracted much attention. It can activate endothelial nitric oxide synthase (eNOS), promoting the release of nitric oxide (NO), resulting in relaxation of vascular smooth muscle. In isolated vascular ring experiments, Ara-U (1 μM) could induce a 60% dilation of the aortic ring, and this effect could be completely blocked by the NO synthesis inhibitor L-NAME. These findings provide a structural template for the development of new cardiovascular drugs.

The application of Ara-U in biochemical research extends to multiple technical aspects. As an RNA synthesis inhibitor, Ara-U is widely used in the study of synchronizing the cell cycle. By briefly treating the cells, G1/S phase arrest can be achieved, providing a time window for analyzing cell cycle regulatory proteins. In RNA labeling techniques, after Ara-U is coupled with biotin or fluorescent groups, it can be used as a nucleic acid probe to track RNA dynamic changes. For instance, Ara-U-biotin probes have been successfully used to visualize the transport path of viral RNA within cells.

Furthermore, Ara-U is also an important tool for studying the nucleoside metabolic pathway. It can inhibit the activity of uracil nucleoside kinase and interfere with the phosphorylation process of uracil nucleosides, thereby revealing the regulatory mechanism of the nucleoside metabolic network. In drug screening, Ara-U is used as a positive control to evaluate the activity and selectivity of new antiviral compounds. Its clear mechanism of action and quantifiable biological effects make it a standard reference in the development of antiviral drugs.